Archive for December 2022

Beth Israel Lahey Health has committed to additional concessions over the closure of a Beverly holistic-birthing center it shut down on Dec. 1, following negotiations with the AG’s office, including extending the building lease and hiring more staff locally. Read More

The North Beacon Street property could now be home to Boston Light and Sound, a nationally known vendor on the film festival circuit. Read More

Three and a half years after licensing it from an Israeli pharma in a $142 million deal, Vericel Corporation has won FDA approval for NexoBrid, a gel designed to treat serious burns. Read More

Beacon Hill seems to have more money than it knows what to do with these days, and lawmakers could soon have even fewer options at their disposal. Read More

The Great Resignation may be slowing down, but C-suite executives were still on the move this year. Let’s take a look at some of the most notable executive appointments this year and what they have to say about leading their companies into 2023. Read More

Two of the state’s fastest-growing cities have become hotspots for multifamily housing development. Read More

Artificial intelligence (AI) and automated systems are increasingly affecting our daily lives. But without adequate guidelines and useful directives, the undisciplined use of AI poses risks to the wellbeing of individuals and creates fertile ground for economic, political, social, and criminal exploitation. Read More

An Atlanta-based REIT has sold a second office building in the heart of Cambridge’s Harvard Square, this one to a San Francisco-based firm for $79.2M. It’s exiting the Cambridge submarket with this deal. Read More

Just nine IPOs were recorded among Boston-area companies in 2022, after more than two dozen went public in 2021. In fact, 10 IPOs last year raised more money than this year’s largest, HilleVax. Here’s the infection Hillevax hopes to tackle. Read More

A report released by the House Energy and Commerce Committee paints a damning picture of the approval process for aducanumab, generically known as Aduhelm, the first Alzheimer’s drug made by Biogen Inc. and Eisai Inc. Read More